Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

November 10, 2021 Auto Bot blueprint-medicines, Greater China, Pharma, Zai Lab 0

Shots:

  • Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally
  • Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in  Greater China & will lead the development costs for both products
  • The collaboration combines Blueprint’s precision therapy expertise with Zai Lab’s development capabilities to accelerate the global development of BLU-945 & BLU-701 for NSCLC. Additionally, BLU-945 is currently being evaluated in the P-I/II SYMPHONY trial for EGFR-driven NSCLC & P-I/II trial of BLU-701 is expected to initiate in Q4’21

Click here to­ read the full press release/ article | Ref: PR Newswire | Image: PR Newswire

The post Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China first appeared on PharmaShots.